

IN THE SPECIFICATION

Please amend as follows:

Please replace paragraph [0048] on page 17.

[0048] **FIGURE 15** depicts the human KSR nucleic acid and protein sequence annotated with the locations of the CA1 to CA5 domains and the target sequences for AS-ODNs. The CA1 through CA5 domains correspond respectively to SEQ ID NOS: 26, 40, 41, 42 and 43. The target amino acid sequences for AS-ODNs correspond to SEQ IDs as follows: AS-ODN3(42-47) (SEQ ID NO:17); AS-ODN2(52-57) (SEQ ID NO:18); AS-ODN1(63-68) (SEQ ID NO:19). The full length human KSR1 protein is predicted to have 866 amino acids.

Please replace paragraph [0049] on page 17.

[0049] **FIGURE 16** depicts the mouse KSR nucleic acid and protein sequence annotated with the locations of the CA1 to CA5 domains and the target sequences for the AS-ODNs. The CA1 through CA5 domains correspond respectively to SEQ ID NOS: 2, 44, 45, 46 and 47. The target amino acid sequences for AS-ODNs correspond to SEQ IDs as follows: AS-ODN3(51-56) (SEQ ID NO:17); AS-ODN2(61-66) (SEQ ID NO:18); AS-ODN1(72-77) (SEQ ID NO:19).

Please replace paragraph [0050] on page 17.

[0050] **FIGURE 17** depicts the human KSR-1 full length mRNA sequence with the nucleic acid target sequences for human AS-ODN1 through AS-ODN12 depicted. The target nucleic acid sequences for AS-ODNs correspond to SEQ IDs as follows: AS-ODN4(1-18) (SEQ ID NO:48); AS-ODN3(124-141) (SEQ ID NO:3); AS-ODN2(154-171) (SEQ ID NO:27); AS-ODN1(187-204) (SEQ ID NO:5); AS-ODN5(205-222) (SEQ ID NO:49); AS-ODN6(247-264) (SEQ ID NO:50); AS-ODN7(298-315) (SEQ ID NO:51); AS-ODN8(321-338) (SEQ ID NO:52); AS-

ODN9(351-368) (SEQ ID NO:53); AS-ODN10(379-396) (SEQ ID NO:54); AS-ODN11(511-528) (SEQ ID NO:55); AS-ODN12(531-548) (SEQ ID NO:56).

Please replace paragraph [0206] on page 91-92.

[0206] The full length mRNA sequence of human KSR1 has been determined. The sequence is depicted in FIGURE 14 (SEQ ID NO: 24). Antisense oligonucleotides, including those described above, were designed against the CA1 domain of human KSR nucleic acid. The human KSR antisense oligonucleotides are depicted on the annotated human KSR sequence in FIGURE 15. Oligonucleotide AS-ODN1(187-204) (5'CTTTGCCTCTAGGGTCCG 3') (SEQ ID NO: 28) against nucleotides 187 to 204 of the human sequence corresponds in sequence to AS-ODN1(214-231) (SEQ ID NO:8) described above. Thus, AS-ODN1 is complementary to the nucleotides at positions 187-204 and 214-231 of the human and mouse cDNA, respectively. Oligonucleotide AS-ODN3(124-141) (5'CAGCCCGCGCAGACTGCC 3') (SEQ ID NO: 29) against nucleotides 124 to 141 of the human sequence corresponds in sequence to AS-ODN1(151-168) (SEQ ID NO: 6) described above. Thus, AS-ODN3 is complementary to the nucleotides at positions 124-141 and 151-168 of the human and mouse cDNA sequences, respectively. Oligonucleotide AS-ODN2(154-171) is designed against nucleotides 154 to 171 of the human sequence. AS-ODN2 is complementary to nucleotides at positions 154-171 and 181-198 of the human and mouse cDNA, respectively. The human sequence differs by a single base pair in the most 5' bp of the antisense sequence from the mouse sequence in the corresponding position, with the human AS-ODN2(154-171) sequence being 5'**GAGGTCGTTAGACACTGC** 3' (SEQ ID NO: 30) and the mouse sequence being 5'**GAGGTCGTTAGACACTGA** 3' (SEQ ID NO: 7) (the nucleotide difference is set out in bold). FIGURE 16 depicts the annotated mouse KSR cDNA sequence with antisense oligonucleotides indicated. We have compared the original AS-ODN2(181-198) to the revised human AS-ODN2(154-171) and found they inhibited proliferation of PANC-1 cells, which are oncogenic K-ras-dependent human pancreatic cells, nearly identically (FIGURE 18).

Please replace paragraph [0207] on page 92.

[0207] We have designed additional potential AS-ODNs against other nucleotides of human KSR1. These ODNs (AS-ODN4 to AS-ODN12) are marked and annotated on human KSR1 nucleotide sequences in FIGURE 17. TABLE 2 is a list of these newly designed ODNs (SEQ ID NOS: 31-39) with corresponding human nucleotide target sequence (SEQ ID NOS: 48-56).

TABLE 2

<u>AS-ODN ID #</u>	<u>Target Sequence (nt) (5'-3')</u>	<u>Sequence (5' to 3')</u>
AS-ODN4	ATGGGAGAGAAGGAGGGC (1-18) (<u>SEQ ID NO:48</u>)	GCCCTCCTTCTCTCCCAT (<u>SEQ ID NO:31</u>)
AS-ODN5	CTGGTCCGTTACATTTGT (205-222) (<u>SEQ ID NO:49</u>)	ACAAATGTAACGGACCAG (<u>SEQ ID NO:32</u>)
AS-ODN6	GTGGCTCCCGGTGAGAGG (247-264) (<u>SEQ ID NO:50</u>)	CCTCTCACCGGGAGCCAC (<u>SEQ ID NO:33</u>)
AS-ODN7	GACTGGCTGTACACTTTC (298-315) (<u>SEQ ID NO:51</u>)	GAAAGTGTACAGCCAGTC (<u>SEQ ID NO:34</u>)
AS-ODN8	GAGGCCGGAGGTGGTGCA (321-338) (<u>SEQ ID NO:52</u>)	TGCACCACCTCCGGCCTC (<u>SEQ ID NO:35</u>)
AS-ODN9	AGATCCCCCGAGACCTCA (351-368) (<u>SEQ ID NO:53</u>)	TGAGGTCTCGGGGGATCT (<u>SEQ ID NO:36</u>)
AS-ODN10	ATGAATGAGGCCAAGGTG (379-396) (<u>SEQ ID NO:54</u>)	CACCTTGGCCTCATTCAT (<u>SEQ ID NO:37</u>)
AS-ODN11	AGTTGGAGTTCATTGGAT (511-528) (<u>SEQ ID NO:55</u>)	ATCCAATGAACCTCAACT (<u>SEQ ID NO:38</u>)
AS-ODN12	GCGGCGGGAAAGTGGCTC (531-548) (<u>SEQ ID NO:56</u>)	GAGCCACTTTCCCGCCGC (<u>SEQ ID NO:39</u>)